Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
VLX Ventures is a venture capital firm and technological incubator based in Jerusalem, Israel. Founded as a partnership between Xenia Venture Capital and Van Leer Ventures, VLX Ventures operates under a government-licensed incubator status, which allows it to access co-funding from the Israel Innovation Authority. This unique structure enables VLX to support startups in the biopharma sector through intensive research and development, business validation, and the establishment of innovative companies.
The firm focuses on drug development and computational biology, aiming to transform innovative ideas into impactful realities. VLX Ventures has a diverse portfolio that includes companies at various stages, from early pre-clinical to advanced Phase 3 clinical studies. The firm is committed to addressing challenging diseases through innovative solutions, making it a significant player in the Israeli life sciences ecosystem.
VLX Ventures invests primarily in biopharma therapeutic ventures and digital pharma initiatives that integrate deep biology with computational biology. Their investment strategy encompasses various stages, including pre-seed, seed, seed-plus, and Series A, with a typical seed investment size of approximately $1 million. The firm targets companies that are developing drugs for challenging diseases, reflecting a commitment to advancing precision medicine and diagnostics.
The portfolio spans multiple sectors, including multiomics, cancer therapies, autism treatments, fertility solutions, immunotherapy, anti-infective drugs, targeted neutrophilic therapy, cell therapy for cancer, and ophthalmology. VLX Ventures seeks to partner with founders who demonstrate a strong vision and capability to execute their ideas, emphasizing the importance of innovative research and development in their investment decisions.
VLX Ventures has built a notable portfolio of companies that focus on various aspects of biopharma and digital health. Key portfolio companies include:
This diverse portfolio reflects VLX Ventures' commitment to addressing various challenging diseases through innovative solutions in the biopharma sector.
Ori Choshen: CEO & Board Member. Ori has extensive experience in venture capital and has led multiple successful investments in the biopharma sector.
Eli Sorzon: CFO. Eli brings financial expertise and has a background in managing investments and financial operations within the venture capital space.
Dr. Lior Carmon: CIO. Dr. Carmon has a strong background in computational biology and drug development, contributing to the firm's investment thesis.
Moran Ben David: CBDO. Moran focuses on business development and strategic partnerships, enhancing the firm's portfolio growth.
Anat Tsour Segal: Board Member. Anat has a wealth of experience in the life sciences sector and provides valuable insights into investment decisions.
Erez Meltzer: Board Member. Erez has a strong track record in venture capital and entrepreneurship, contributing to the firm's strategic direction.
Elad Duschak: Board Member. Elad brings expertise in technology and innovation, supporting the firm's focus on computational biology.
To pitch VLX Ventures, founders should send their proposals via email to admin@vlx.co.il. It is essential to include a comprehensive pitch deck that outlines the business model, market opportunity, competitive landscape, and team qualifications. VLX Ventures appreciates detailed information that demonstrates the startup's potential for growth and innovation.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are beneficial but not mandatory. VLX Ventures encourages direct outreach from founders who align with their investment focus.
In recent months, VLX Ventures has continued to expand its portfolio, focusing on innovative biopharma companies. Notable investments include Protica Bio, which specializes in multiomics and cancer therapies, and Point6 Bio, which is working on autism solutions. The firm has also supported Everly Bio in its IVF and fertility initiatives.
VLX Ventures remains active in the Israeli startup ecosystem, leveraging its government-licensed incubator status to co-invest alongside the Israel Innovation Authority. This partnership enhances their ability to support emerging companies in the biopharma sector.
What are VLX Ventures' investment criteria?
VLX Ventures primarily invests in biopharma therapeutic ventures and digital pharma initiatives. They focus on companies that integrate deep biology with computational biology, targeting innovative solutions for challenging diseases.
How can startups apply or pitch to VLX Ventures?
Startups can pitch VLX Ventures by sending an email to admin@vlx.co.il. It is advisable to include a detailed pitch deck outlining the business model, market opportunity, and team background.
What makes VLX Ventures different from other investors?
VLX Ventures operates as both a venture capital firm and a government-licensed incubator, allowing them to access co-funding from the Israel Innovation Authority. This unique structure enhances their ability to support startups through mentoring, networking, and financial backing.
What is the geographic scope of VLX Ventures?
VLX Ventures is based in Jerusalem, Israel, and primarily invests in Israeli startups within the biopharma and digital health sectors.
What is the typical check size for investments?
The typical seed investment size for VLX Ventures is approximately $1 million, with the capacity for follow-on investments as companies progress through their development stages.
What kind of post-investment involvement can startups expect?
VLX Ventures provides significant value to its portfolio companies through mentoring, networking opportunities, financial support, and administrative assistance, ensuring that startups have the resources they need to succeed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.